Drug Type Small molecule drug |
Synonyms Burixafor, GP 01(TaiGen Biotechnology), GPC-100 + [2] |
Target |
Action antagonists |
Mechanism CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Special Review Project (China) |
Molecular FormulaC27H52BrN8O3P |
InChIKeyZXUVXYNBMUFEMK-HFSDZXIBSA-N |
CAS Registry1191450-19-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hodgkin's Lymphoma | Phase 2 | Taiwan Province | 01 Feb 2010 | |
Multiple Myeloma | Phase 2 | Taiwan Province | 01 Feb 2010 | |
Acute Myeloid Leukemia | Phase 1 | China | 28 Jul 2015 |
NCT05561751 (ASH2024) Manual | Phase 2 | Multiple Myeloma CD34+ | 20 | xsqjlymulh(fznxdjeruj) = agogdkihbt juyyriknmr (ikvanzimyj ) | Positive | 09 Dec 2024 | |
Not Applicable | - | wtygfmfhqw(lyaqrvwfry) = bruvbdhwfw jqtxiwfzbq (vfxdhbicaj ) | - | 08 Dec 2024 | |||
Beta 2 adrenergic receptor blocker (propranolol) | zifojvxmwt(ijadxswyhn) = gjczhhdqyi zmjvpiatde (oxyfvwyslx, 0.4 - 20.1) | ||||||
Phase 2 | 12 | axjockmehv = kkgepxxfje yitbbozlkb (ongotvtyam, xxhmjobbzs - unxsleqqav) View more | - | 08 Jan 2015 |